Ovarian Cancer Coverage from Every Angle
Advertisement
Advertisement

Mansoor Raza Mirza, MD, on the Potential Role of PARP Inhibition Plus Immunotherapy in Ovarian Cancer

Posted: Monday, June 17, 2019

Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discusses the clinical implications of study findings on using niraparib plus bevacizumab to treat women with recurrent platinum-sensitive ovarian cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.